You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jul 13, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Nathan C Busse1, Muthana S A L Al-Ghazi2, Nadine Abi-Jaoudeh3
1Colorado Associates in Medical Physics, Denver, Colorado, USA.
This study outlines essential guidelines for establishing Yttrium-90 (90 Y) radioembolization programs. It details medical physicist roles, patient preparation, dose delivery, and safety protocols for treating liver tumors.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: